使用机器人NeuroBlate系统激光消融异常神经组织(LAANTERN):脑肿瘤消融后12个月结局与生活质量
LAANTERN是一项正在进行的多中心前瞻性NeuroBlate激光间质热疗登记研究,纳入14个中心223例接受LITT的颅内肿瘤患者,中位随访223天。结果显示1年估计生存率73%,患者报告的生活质量在术后稳定,KPS平均下降5.7至10.5分,但50.5%的患者在6个月时KPS稳定或改善,转移性与原发性肿瘤患者间KPS或生活质量无显著差异。
要点
- LITT使恶性脑肿瘤患者的生活质量从基线水平稳定并改善。
- 术后KPS平均下降5.7至10.5分,但50.5%在6个月时稳定或改善。
- 转移性与原发性肿瘤患者间KPS或生活质量无显著差异。
核心结论
- LAANTERN登记研究结果表明,LITT使合并症高发的恶性脑肿瘤患者的生活质量从基线水平稳定并改善,总生存优于真实世界登记的预期并与已发表文献相当。
研究设计与样本
- 正在进行的多中心前瞻性NeuroBlate激光间质热疗登记研究,共14个中心纳入223例接受LITT的颅内肿瘤或新生物患者,中位随访223天。
主要发现
- 共纳入223例受试者,女性119例(53.4%),男性104例(46.6%),中位年龄54.3岁(范围3-86岁),72.6%至少有1种基线合并症,基线KPS中位数90。
- 消融肿瘤中原发性131例、转移性92例;原发性肿瘤患者中大多数为高级别胶质瘤(80.9%);转移性肿瘤患者中复发者占50.6%、放射性坏死占40%。
- 术后中位住院时间33.4小时(范围12.7-733.4小时),1年估计生存率73%,且不受疾病病因影响。
- 术后KPS平均下降5.7至10.5分,但50.5%的患者在6个月时KPS稳定或改善;转移性与原发性肿瘤患者间KPS或生活质量无显著差异。
- 采用癌症治疗功能评估-脑模块评估的患者报告生活质量在术后稳定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN) is an ongoing multicenter prospective NeuroBlate (Monteris Medical) LITT (laser interstitial thermal therapy) registry collecting real-world outcomes and quality-of-life (QoL) data. OBJECTIVE: To compare 12-mo outcomes from all subjects undergoing LITT for intracranial tumors/neoplasms. METHODS: Demographics, intraprocedural data, adverse events, QoL, hospitalizations, health economics, and survival data are collected; standard data management and monitoring occur. RESULTS: A total of 14 centers enrolled 223 subjects; the median follow-up was 223 d. There were 119 (53.4%) females and 104 (46.6%) males. The median age was 54.3 yr (range 3-86) and 72.6% had at least 1 baseline comorbidity. The median baseline Karnofsky Performance Score (KPS) was 90. Of the ablated tumors, 131 were primary and 92 were metastatic. Most patients with primary tumors had high-grade gliomas (80.9%). Patients with metastatic cancer had recurrence (50.6%) or radiation necrosis (40%). The median postprocedure hospital stay was 33.4 h (12.7-733.4). The 1-yr estimated survival rate was 73%, and this was not impacted by disease etiology. Patient-reported QoL as assessed by the Functional Assessment of Cancer Therapy-Brain was stabilized postprocedure. KPS declined by an average of 5.7 to 10.5 points postprocedure; however, 50.5% had stabilized/improved KPS at 6 mo. There were no significant differences in KPS or QoL between patients with metastatic vs primary tumors. CONCLUSION: Results from the ongoing LAANTERN registry demonstrate that LITT stabilizes and improves QoL from baseline levels in a malignant brain tumor patient population with high rates of comorbidities. Overall survival was better than anticipated for a real-world registry and comparative to published literature.
引用
- Kim AH, Tatter S, Rao G, et al. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery. 2020. PMID: 32315434. doi:10.1093/neuros/nyaa071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。